RICARDO S. MARTINEZ, Chief District Judge.
In connection with the production of confidential documents and other confidential information in this action, Plaintiffs Gilbert Hoang Nguyen and Susan Tan and Defendants Juno Therapeutics, Inc. ("Juno"), Hans E. Bishop, Steven D. Harr, and Mark J. Gilbert, through their respective counsel, enter into this Stipulated Protective Order for the Treatment of Designated Information.
Discovery in this action is likely to involve production of confidential, proprietary, or private information for which special protection may be warranted. Accordingly, the parties hereby stipulate to and petition the Court to enter the following Stipulated Protective Order. The purpose of this Stipulated Protective Order is to provide a means for limiting access to, use, and disclosure of confidential material (as defined below) produced in this action while affording public disclosure to the greatest extent possible. The parties acknowledge that this agreement is consistent with LCR 26(c). It does not confer blanket protection on all disclosures or responses to discovery, the protection it affords from public disclosure and use extends only to the limited information or items that are entitled to confidential treatment under the applicable legal principles, and it does not presumptively entitle parties to file confidential material (as defined below) under seal.
"Confidential" material shall include the following documents, deposition testimony, information, and other tangible or intangible items produced or otherwise exchanged:
(i) non-public intellectual property or proprietary information, including, but not limited to, research, data, technical specifications, designs, processes, production methods, cost or pricing regarding any Juno product, or any communications concerning the foregoing;
(ii) non-public communications concerning development, testing, or analyses of pre-clinical and clinical-stage pharmaceutical products;
(iii) non-public communications with any governmental regulatory or supervisory agency, body or group;
(iv) non-public clinical study data and analyses;
(v) non-public information pertaining or referring to Juno's regulatory, financial, business development or marketing plans or practices that, if disclosed, could damage Juno's competitive position;
(vi) non-public information obtained from a non-party pursuant to a non-disclosure agreement, or that the producing party is under a legal or contractual obligation to maintain as confidential;
(viii) non-public terms of commercial agreements, licensing agreements, collaboration agreements, clinical trial agreements, sponsored research agreements, settlement agreements or communications pertaining to such agreements.
The protections conferred by this agreement cover not only confidential material (as defined above), but also (1) any information copied or extracted from confidential material; (2) all copies, excerpts, summaries, or compilations of confidential material; and (3) any testimony, conversations, or presentations by parties or their counsel that might reveal confidential material.
However, the protections conferred by this agreement do not cover information that is in the public domain or becomes part of the public domain through trial or otherwise.
4.1
4.2
(a) the receiving party's counsel of record in this action, as well as employees of counsel to whom it is reasonably necessary to disclose the information for this litigation;
(b) the officers, directors, and employees (including in-house counsel) of the receiving party to whom disclosure is reasonably necessary for this litigation;
(c) experts and consultants to whom disclosure is reasonably necessary for this litigation and who have signed the "Acknowledgment and Agreement to Be Bound" (Exhibit A);
(d) the Court, court personnel, and court reporters and their staff;
(e) copy or imaging services retained by counsel to assist in the duplication of confidential material, provided that counsel for the party retaining the copy or imaging service instructs the service not to disclose any confidential material to third parties and to immediately return all originals and copies of any confidential material;
(f) during their depositions, any witness to whom disclosure is reasonably necessary who is not otherwise permitted to view confidential material pursuant to this agreement and who has signed the "Acknowledgment and Agreement to Be Bound" (Exhibit A), unless otherwise agreed by the designating party or ordered by the Court. Pages of transcribed deposition testimony or exhibits to depositions that reveal confidential material must be separately bound by the court reporter and may not be disclosed to anyone except as permitted under this agreement;
(g) the author or recipient of a document containing the information or a custodian or other person who otherwise possessed or knew the information; or
(h) any mediator who the parties agree to use in the event the parties pursue mediation, and any such mediator's employees to whom disclosure is reasonably necessary for the mediation.
4.3
5.1
Mass, indiscriminate, or routinized designations are prohibited. Designations that are shown to be clearly unjustified or that have been made for an improper purpose (e.g., to unnecessarily encumber or delay the case development process or to impose unnecessary expenses and burdens on other parties) expose the designating party to sanctions.
If it comes to a designating party's attention that information or items that it designated for protection do not qualify for protection, the designating party must promptly notify all other parties that it is withdrawing the mistaken designation.
5.2
(a)
(b)
(c)
5.3
6.1
6.2
6.3
If a party is served with a subpoena or a court order issued in other litigation that compels disclosure of any information or items designated in this action as "CONFIDENTIAL," that party must:
(a) promptly notify the designating party in writing and include a copy of the subpoena or court order;
(b) promptly notify in writing the party who caused the subpoena or order to issue in the other litigation that some or all of the material covered by the subpoena or order is subject to this agreement. Such notification shall include a copy of this agreement; and
(c) cooperate with respect to all reasonable procedures sought to be pursued by the designating party whose confidential material may be affected.
If a receiving party learns that, by inadvertence or otherwise, it has disclosed confidential material to any person or in any circumstance not authorized under this agreement, the receiving party must immediately (a) notify in writing the designating party of the unauthorized disclosures, (b) use its best efforts to retrieve all unauthorized copies of the protected material, (c) inform the person or persons to whom unauthorized disclosures were made of all the terms of this agreement, and (d) request that such person or persons execute the "Acknowledgment and Agreement to Be Bound" that is attached hereto as Exhibit A.
When a producing party gives notice to receiving parties that certain inadvertently produced material is subject to a claim of privilege or other protection, the obligations of the receiving parties are those set forth in Federal Rule of Civil Procedure 26(b)(5)(B). This provision does not, however, alter the provisions of the parties' Stipulation Regarding Discovery of Electronically Stored Information. The parties agree to the entry of a non-waiver order under Fed. R. Evid. 502(d) as set forth herein.
Within 60 days after the termination of this action, including all appeals, each receiving party must either return or destroy all confidential material to the producing party, including all copies, extracts, and summaries thereof. Notwithstanding this provision, counsel are entitled to retain one archival copy of all documents filed with the Court; trial, deposition, and hearing transcripts; correspondence; deposition and trial exhibits; expert reports; attorney work product; and consultant and expert work product, even if such materials contain confidential material.
The confidentiality obligations imposed by this agreement shall remain in effect until a designating party agrees otherwise in writing or a court orders otherwise.
IT IS SO STIPULATED, THROUGH COUNSEL OF RECORD.
PURSUANT TO STIPULATION, IT IS SO ORDERED.
IT IS FURTHER ORDERED that pursuant to Fed. R. Evid. 502(d), the production of any documents in this proceeding shall not, for the purposes of this proceeding or any other proceeding in any other court, constitute a waiver by the producing party of any privilege applicable to those documents, including the attorney-client privilege, attorney work-product protection, or any other privilege or protection recognized by law.
I, ____________________________________ [print or type full name], of ____________________________________ [print or type full address], declare under penalty of perjury that I have read in its entirety and understand the Stipulated Protective Order that was issued by the United States District Court for the Western District of Washington on [date] in the case of In re Juno Therapeutics, Inc., No. C16-1069 RSM. I agree to comply with and to be bound by all the terms of this Stipulated Protective Order and I understand and acknowledge that failure to so comply could expose me to sanctions and punishment in the nature of contempt. I solemnly promise that I will not disclose in any manner any information or item that is subject to this Stipulated Protective Order to any person or entity except in strict compliance with the provisions of this Order.
I further agree to submit to the jurisdiction of the United States District Court for the Western District of Washington for the purpose of enforcing the terms of this Stipulated Protective Order, even if such enforcement proceedings occur after termination of this action.